Ligand id: 5936

Name: nintedanib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: nintedanib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 94.22
Molecular weight 539.25
XLogP 3.14
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Nintedanib was originally approved as a treatment for idiopathic pulmonary fibrosis. Subsequently it has been approved (by the FDA) to slow pulmonary fuction decline in patients with systemic sclerosis-associated interstitial lung diseases (ILD).
Click here to link to current list of nintedanib studies.
In October 2019 the FDA granted Breakthrough Therapy Designation to nintedanib for the treatment of progressive chronic fibrosing ILD, based on preliminary results from the Phase 3 INBUILD trial (NCT02999178). This resulted in full approval for this indication in March 2020.
Mechanism Of Action and Pharmacodynamic Effects
Nintedanib inhibits multiple angiogenic pathways, and appears to also inhibit pathways associated with the fibrotic scarring of the lung observed in idiopathic pulmonary fibrosis (IPF). In tumours inhibition of VEGF receptor (VEGFR), PDGFR and FGFR kinase activity reduces tumour angiogenesis/neo-vascularisation, thereby restricitng tumour expansion [2]. The mechanism in IPF is less clear. See [1] and [3] for further information.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02999178 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Phase 3 Interventional Boehringer Ingelheim
External links